The newly created doxorubicin-melittin polymersome (Dox-Mel PL) drug delivery system was capable of controlling MDR cancer cells and offered the following benefits: (1) biocompatible polymersome (a poly lactic acid-hyaluronic acid (20k–10k) di-block copolymer) promote synergistic effects of the simultaneous administration of Dox (anticancer agent) and Mel (a major component of bee venom); (2) reduction of Dox and Mel side effects; and (3) downregulation of P-gp by Mel prevent drug resistance. This evidence concerns the gene PGP and cancer.